ZFP42 and neurodevelopmental disorder: These findings suggest that approaches to activate SRPKs or normalize expression of REX1, for example using protein degradation technologies, such as proteolysis targeting chimeras (PROTACs), might provide therapeutic benefit in patients with neurodevelopmental disorders underpinned by deregulated SRPK-RNF12 signaling.